Maros Ferencik1,2, Thomas Mayrhofer2,3, Daniel O Bittner2,4, Hamed Emami2, Stefan B Puchner2,5, Michael T Lu2, Nandini M Meyersohn2, Alexander V Ivanov2, Elizabeth C Adami2, Manesh R Patel6, Daniel B Mark6, James E Udelson7, Kerry L Lee6, Pamela S Douglas6, Udo Hoffmann2. 1. Knight Cardiovascular Institute, Oregon Health and Science University, Portland. 2. Cardiac MR PET CT Program, Massachusetts General Hospital, Harvard Medical School, Boston. 3. School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany. 4. Department of Cardiology, University Hospital Erlangen, Friedrich-Alexander University, Erlangen-Nürnberg, Germany. 5. Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 6. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 7. Tufts University School of Medicine and the Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.
Abstract
Importance: Coronary computed tomographic angiography (coronary CTA) can characterize coronary artery disease, including high-risk plaque. A noninvasive method of identifying high-risk plaque before major adverse cardiovascular events (MACE) could provide practice-changing optimizations in coronary artery disease care. Objective: To determine whether high-risk plaque detected by coronary CTA was associated with incident MACE independently of significant stenosis (SS) and cardiovascular risk factors. Design, Setting, and Participants: This prespecified nested observational cohort study was part of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. All stable, symptomatic outpatients in this trial who required noninvasive cardiovascular testing and received coronary CTA were included and followed up for a median of 25 months. Exposures: Core laboratory assessment of coronary CTA for SS and high-risk plaque (eg, positive remodeling, low computed tomographic attenuation, or napkin-ring sign). Main Outcomes and Measures: The primary end point was an adjudicated composite of MACE (defined as death, myocardial infarction, or unstable angina). Results: The study included 4415 patients, of whom 2296 (52%) were women, with a mean age of 60.5 years, a median atherosclerotic cardiovascular disease (ASCVD) risk score of 11, and a MACE rate of 3% (131 events). A total of 676 patients (15.3%) had high-risk plaques, and 276 (6.3%) had SS. The presence of high-risk plaque was associated with a higher MACE rate (6.4% vs 2.4%; hazard ratio, 2.73; 95% CI, 1.89-3.93). This association persisted after adjustment for ASCVD risk score and SS (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.13-2.62). Adding high-risk plaque to the ASCVD risk score and SS assessment led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). Presence of high-risk plaque increased MACE risk among patients with nonobstructive coronary artery disease relative to patients without high-risk plaque (aHR, 4.31 vs 2.64; 95% CI, 2.25-8.26 vs 1.49-4.69). There were no significant differences in MACE in patients with SS and high-risk plaque as opposed to those with SS but not high-risk plaque (aHR, 8.68 vs. 9.31; 95% CI, 4.25-17.73 vs 4.21-20.61). High-risk plaque was a stronger predictor of MACE in women (aHR, 2.41; 95% CI, 1.25-4.64) vs men (aHR, 1.40; 95% CI, 0.81-2.39) and younger patients (aHR, 2.33; 95% CI, 1.20-4.51) vs older ones (aHR, 1.36; 95% CI, 0.77-2.39). Conclusions and Relevance: High-risk plaque found by coronary CTA was associated with a future MACE in a large US population of outpatients with stable chest pain. High-risk plaque may be an additional risk stratification tool, especially in patients with nonobstructive coronary artery disease, younger patients, and women. The importance of findings is limited by low absolute MACE rates and low positive predictive value of high-risk plaque. Trial Registration: clinicaltrials.gov Indentifier: NCT01174550.
RCT Entities:
Importance: Coronary computed tomographic angiography (coronary CTA) can characterize coronary artery disease, including high-risk plaque. A noninvasive method of identifying high-risk plaque before major adverse cardiovascular events (MACE) could provide practice-changing optimizations in coronary artery disease care. Objective: To determine whether high-risk plaque detected by coronary CTA was associated with incident MACE independently of significant stenosis (SS) and cardiovascular risk factors. Design, Setting, and Participants: This prespecified nested observational cohort study was part of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. All stable, symptomatic outpatients in this trial who required noninvasive cardiovascular testing and received coronary CTA were included and followed up for a median of 25 months. Exposures: Core laboratory assessment of coronary CTA for SS and high-risk plaque (eg, positive remodeling, low computed tomographic attenuation, or napkin-ring sign). Main Outcomes and Measures: The primary end point was an adjudicated composite of MACE (defined as death, myocardial infarction, or unstable angina). Results: The study included 4415 patients, of whom 2296 (52%) were women, with a mean age of 60.5 years, a median atherosclerotic cardiovascular disease (ASCVD) risk score of 11, and a MACE rate of 3% (131 events). A total of 676 patients (15.3%) had high-risk plaques, and 276 (6.3%) had SS. The presence of high-risk plaque was associated with a higher MACE rate (6.4% vs 2.4%; hazard ratio, 2.73; 95% CI, 1.89-3.93). This association persisted after adjustment for ASCVD risk score and SS (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.13-2.62). Adding high-risk plaque to the ASCVD risk score and SS assessment led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). Presence of high-risk plaque increased MACE risk among patients with nonobstructive coronary artery disease relative to patients without high-risk plaque (aHR, 4.31 vs 2.64; 95% CI, 2.25-8.26 vs 1.49-4.69). There were no significant differences in MACE in patients with SS and high-risk plaque as opposed to those with SS but not high-risk plaque (aHR, 8.68 vs. 9.31; 95% CI, 4.25-17.73 vs 4.21-20.61). High-risk plaque was a stronger predictor of MACE in women (aHR, 2.41; 95% CI, 1.25-4.64) vs men (aHR, 1.40; 95% CI, 0.81-2.39) and younger patients (aHR, 2.33; 95% CI, 1.20-4.51) vs older ones (aHR, 1.36; 95% CI, 0.77-2.39). Conclusions and Relevance: High-risk plaque found by coronary CTA was associated with a future MACE in a large US population of outpatients with stable chest pain. High-risk plaque may be an additional risk stratification tool, especially in patients with nonobstructive coronary artery disease, younger patients, and women. The importance of findings is limited by low absolute MACE rates and low positive predictive value of high-risk plaque. Trial Registration: clinicaltrials.gov Indentifier: NCT01174550.
Authors: Edward A Hulten; Salvatore Carbonaro; Sara P Petrillo; Joshua D Mitchell; Todd C Villines Journal: J Am Coll Cardiol Date: 2010-12-08 Impact factor: 24.094
Authors: Lin Wang; Gary S Mintz; Bernhard Witzenbichler; D Christopher Metzger; Michael J Rinaldi; Peter L Duffy; Giora Weisz; Thomas D Stuckey; Bruce R Brodie; Shinji Inaba; Ke Xu; Ajay J Kirtane; Gregg W Stone; Akiko Maehara Journal: JACC Cardiovasc Imaging Date: 2015-07-15
Authors: Benjamin J W Chow; Gary Small; Yeung Yam; Li Chen; Stephan Achenbach; Mouaz Al-Mallah; Daniel S Berman; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Victor Cheng; Kavitha M Chinnaiyan; Augustin Delago; Allison Dunning; Martin Hadamitzky; Jörg Hausleiter; Philipp Kaufmann; Fay Lin; Erica Maffei; Gilbert L Raff; Leslee J Shaw; Todd C Villines; James K Min Journal: Circ Cardiovasc Imaging Date: 2011-07-05 Impact factor: 7.792
Authors: G B John Mancini; Pamela M Hartigan; Eric R Bates; Steven P Sedlis; David J Maron; John A Spertus; Daniel S Berman; William J Kostuk; Leslee J Shaw; William S Weintraub; Koon K Teo; Marcin Dada; Bernard R Chaitman; Robert A O'Rourke; William E Boden Journal: Circ Cardiovasc Interv Date: 2011-11-01 Impact factor: 6.546
Authors: Juan Ruiz-García; Amir Lerman; Giora Weisz; Akiko Maehara; Gary S Mintz; Martin Fahy; Ke Xu; Alexandra J Lansky; Ecaterina Cristea; Tony G Farah; Rui Teles; Hans Erik Botker; Barry Templin; Zhen Zhang; Bernard de Bruyne; Patrick W Serruys; Gregg W Stone Journal: EuroIntervention Date: 2012-12-20 Impact factor: 6.534
Authors: Ricardo C Cury; Suhny Abbara; Stephan Achenbach; Arthur Agatston; Daniel S Berman; Matthew J Budoff; Karin E Dill; Jill E Jacobs; Christopher D Maroules; Geoffrey D Rubin; Frank J Rybicki; U Joseph Schoepf; Leslee J Shaw; Arthur E Stillman; Charles S White; Pamela K Woodard; Jonathon A Leipsic Journal: J Cardiovasc Comput Tomogr Date: 2016-06-15
Authors: Udo Hoffmann; Michael T Lu; Devvora Olalere; Elizabeth C Adami; Michael T Osborne; Alex Ivanov; John Sukumar Aluru; Saeyun Lee; Nadja Arifovic; Edgar Turner Overton; Carl J Fichtenbaum; Judith A Aberg; Beverly Alston-Smith; Karin L Klingman; Myron Waclawiw; Tricia H Burdo; Kenneth C Williams; Markella V Zanni; Patrice Desvigne-Nickens; Katharine Cooper-Arnold; Kathleen V Fitch; Heather Ribaudo; Pamela S Douglas; Steven K Grinspoon Journal: Am Heart J Date: 2019-03-04 Impact factor: 4.749
Authors: Sahar Taqui; Maros Ferencik; Brian P Davidson; J Todd Belcik; Federico Moccetti; Michael Layoun; Jacob Raber; Mitchell Turker; Hagai Tavori; Sergio Fazio; Jonathan R Lindner Journal: J Am Soc Echocardiogr Date: 2019-05-15 Impact factor: 5.251
Authors: Jacek Kwiecinski; Damini Dey; Sebastien Cadet; Sang-Eun Lee; Yuka Otaki; Phi T Huynh; Mhairi K Doris; Evann Eisenberg; Mijin Yun; Maurits A Jansen; Michelle C Williams; Balaji K Tamarappoo; John D Friedman; Marc R Dweck; David E Newby; Hyuk-Jae Chang; Piotr J Slomka; Daniel S Berman Journal: JACC Cardiovasc Imaging Date: 2019-02-13
Authors: Stijn Devuyst; Arno Gigase; Jerrold Spapen; Sofie Brouwers; Thomas Couck; Jeroen Sonck; Takuya Mizukami; Carlo Gigante; Herbert de Raedt; Dan Schelfaut; Ward Heggermont; Bernard De Bruyne; Martin Penicka; Guy Van Camp; Carlos Collet Journal: Cardiovasc Diagn Ther Date: 2019-06
Authors: Jacek Kwiecinski; Damini Dey; Sebastien Cadet; Sang-Eun Lee; Balaji Tamarappoo; Yuka Otaki; Phi T Huynh; John D Friedman; Mark R Dweck; David E Newby; Mijin Yun; Hyuk-Jae Chang; Piotr J Slomka; Daniel S Berman Journal: Eur Heart J Cardiovasc Imaging Date: 2020-01-01 Impact factor: 6.875